Explore Stanford technologies available for licensing:

Recent advances in cancer immunotherapy and sequencing technologies have created promising opportunities for precision cancer medicine.

Stanford researchers at the Xing Lab have developed a dosimetric features driven- machine learning model for dose volume histograms (DVHs) and dose prediction for volumetric modulated arc therapy (VMAT) planning.

Background:

Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors

Disease Indication: Pain relief

Drug Format: Small molecule

Drug Class: First in class

Research Stage: In vitro/Lead selection

Target: CB1R

Stanford researchers have demonstrated the application of pulsed Focused Ultrasound (pFUS), to non-invasively enhance the function and engraftment of pancreatic islets following transplantation.

The Hong Neurotechnology Lab at Stanford University developed ultrasound-activated nanoscopic light emitters (mechanoluminescent nanoparticles) that are delivered via the blood stream, unlike conventional optogenetics approaches that require invasive fiber optic implants.

Researchers in Prof. A.C. Matin's laboratory have developed a versatile exosome (extracellular vesicle, "EV") drug delivery platform that can selectively target therapeutic agents to tumors or other tissues that overexpress extracellular receptors.

Researchers at Stanford have shown that two CRISPR-Cas nucleases, Cas9 and Cpf1, can be programmed to produce efficient RNA-guided nickases.

Stanford researchers have developed a rapid, accurate, and accessible method to test for food allergy and other types of allergy.

Disease Indication Oncology, hematological cancers, breast cancer, solid tumors

Drug Format Cell therapy

Drug Class Best-in-class

Target CD19, HER2, B7-H3, GPC2 and all other tumor antigens

This bandage-like multi-lead, continuous ECG monitoring device uses new stretchable electrode material developed in the Bao group to accurately and imperceptibly diagnose cardiac arrhythmia.

Researchers at Stanford have developed a device capable of delivering ultrasonic neuromodulation to defined areas of the brain while simultaneously recording neuronal activity with cell-type specificity.

Stanford researchers at the Prakash Lab have developed Octopi, a low-cost ($250-$500) and reconfigurable autonomous microscopy platform capable of automated slide scanning and correlated bright-field and fluorescence imaging.

Researchers at Stanford have developed a novel therapeutic approach for dilated cardiomyopathy (DCM). DCM is characterized by left ventricular enlargement and reduced systolic function.